The Comparisons of Safety and Efficacy in Using Different Anticoagulants after Left Atrial Appendage Closure with Watchman Device

Fu Guohua, Wang Binhao, He Bin, Liu Jing, Yu Yibo, Feng Mingjun, Du Xianfeng, Gao Fang, Chu Huimin. Arrhythmia Center, Ningbo First Hospital, Ningbo 315000, China. Corresponding author: Chu Huimin, Email: epnbheart@163.com

【Abstract】Objective To investigate the safety and efficacy of using different anticoagulants after left atrial appendage closure with Watchman device. Methods Patients with successfully Watchman device implanted were included. All the patients were received anticoagulants within 45 days after the procedure (including warfarin, rivaroxaban and dabigatran). Results A total of 285 patients were consecutively selected. The study population was divided into 3 groups: warfarin group (n=80), dabigatran group (n=114), and rivaroxaban group (n=91). The peri-procedure complications and device-related thrombus (2.5% vs 0.8% vs 1.1%, P=0.803) were comparable between groups. Conclusion The safety and efficacy of dabigatran and rivaroxaban was comparable with warfarin within 45 days after Watchman device implantation.

【Key words】Atrial fibrillation, percutaneous left atrial appendage closure, anticoagulants